The emerging role of clozapine in the treatment of improvement disorders

Movement Disorders

Volumn 12, Issue 4, 1997, Pages 483-496

  Factor, Stewart A ^a   Friedman, Joseph H ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Clozapine; Hyperkinetic movement disorders; Parkinson's disease; Psychosis and parkinsonism; Tardive dyskinesia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

AKATHISIA; DRUG INDUCED DISEASE; DYSKINESIA; ESSENTIAL TREMOR; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TARDIVE DYSKINESIA; TREMOR;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DYSKINESIA, DRUG-INDUCED; HUMANS; HUNTINGTON DISEASE; MOVEMENT DISORDERS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; TREMOR;

EID: 0030819935     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120403     Document Type: Review

References (148)

1. Freyhan FA. Psychomotility and parkinsonisra in treatment with neuroleptic drugs. Arch Neural Psychiatry 1957;78:465-472.
2. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11: 490-493.
3. Ehringer H, Homykiewicz O. Verteilung von noradrenalen und dopamin (3-hydroxytyramine) im gehim des menschen und ihr berhatten bei erhankingen des extrapyramidalen systems. Klin Wochenschr. 1960;24:1236-1239.
4. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
5. Goodwin F. Psychiatrie side effects of levodopa in man. JAMA 1971;218:18-22.
6. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neural 1970;23:193-200.
7. Friedman AJ, Sienkiewicz J. Psychotic complications of levodopa treatment of Parkinson's disease. Acta Neural Scand 1991 ;84: 111-113.
8. Jenkins RB, Groh RH. Mental symptoms in Parkinson patients treated with L-DOPA. Lancet 1970;II:177-180.
9. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman AG, Rail TW, Nies AS, Taylor P eds. Goodman and Oilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:383-436.
10. Haase HY. Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drags. Rev Can Biol 1961;20:425-449.
11. Kaplan HI, Saddock BJ. Synopsis of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1991.
12. Friedman JH. Drug-induced parkinsonism. In: Lang AE, Weiner WJ, eds. Drug induced movement disorders. Mt. Kisco, NY: Futura, 1992:41-83.
13. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
14. Van Toi HH, Bunzow JR, Guen HC, et al. Cloning of the gene for a human D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
15. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP. Antiglutamatergic effects of clozapine. Neurosd Lett 1993;163:155-158.
16. Wolters ECH, HurwitzTA, Peppard RF, Calne DB. Clozapine: an antipsychotic agent for Parkinson's disease? Clin Neurophannacol 1989;12:83-90.
17. Meltzer HY, Stockmeier CA. In vivo occupancy of dopamine receptors by antipsychotic drags. Arch Gen Psychiatry 1992;49: 588-589.
18. Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49: 345-353.
19. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in the CHO-K 1 cell. Eur J Pharmacol 1991; 192:205-206.
20. Bunney BS. Clozapine:.a hypothesized mechanism for its unique clinical profile. Br J Psychiatry 1992;160(suppl 17):17-21.
21. Kastrup O, Gastpar M, Schwarz M. Acute dystonia due to clozapine. J Neural Neurosurg Psychiatry 1994;57:119.
22. Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapineinduced neuroleptic malignant syndrome. J Clin Psychiatry 1991; 52:99-101.
23. Pope HG, Cole JO, Choras PT, Fulwiler CE. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986:174:493-495.
24. Hermesh H, Aizenberg D, Weizman A, et al. Risk for definite neuroleptic malignant syndrome: a prospective study in 223 consecutive in-patients. Br J Psychiatry 1992;161:254-257.
25. Factor SA, Singer C. Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ, eds. Drug induced movement disorders. Mt. Kisco, NY: Futura, 1992:199-230.
26. Juul-Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients, treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
27. Gerlach J, Jorgensen EO, Peacock L. Long-term experience with clozapine in Denmark: research and clinical practice. Psychopharmacology (Bert) 1989;99(suppl):S92-S96.
28. Ekblom B, Haggstrom JE. Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 1974:16:945-957
29. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796.
30. Regis E. Precis de psychiatrie. Paris: Gaston Doiz, 1906.
31. Jackson JA, Free GBM, Pike HV. The psychic manifestations in paralysis agitans. Arch Neural Psychiatry 1923;10:6SO-684.
32. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy Body disease and progressive dementia. Neurology 1988:38:1520-1528.
33. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14:283-295.
34. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neural 1995;65: 115-138.
35. Golden WE, Lavender PC, Metzer WS. Acute postoperative con-fusion and hallucinations in Parkinson's disease. Ann Intent Med 1989;111:218-222.
36. Greene P, Coté L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neural 1993;60:703706.
37. Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991:14:273-278.
38. Klawans HL. Levodopa-induced psychosis. Psychiatr Ann 1978; 8:447-451.
39. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
40. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study [Abstract]. Ann Neural 1983:14:136.
41. Sanchez-Ramos JR, Ortoll R, Singer C, Shulman L, Weiner WJ, Paulson G. Visual hallucinations in Parkinson's disease [Abstract]. Ann Neural 1993;34:264-265.
42. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993:43:2227-2229.
43. Feldman RG, Kaye JA, Lannon MC. Parkinson's disease: follow up after "drug holiday." J Clin Phannacol 1986;26:662-667.
44. Friedman JH. Drag holidays in the treatment of Parkinson's disease: a brief review. Arch Intern Med 1985:145:913-915.
45. Goetz CG, Tanner CM, Klawans HL. Drug holidays in the management of Parkinson's disease. Clin Neurophannacol 1982;5: 351-364.
46. Mayeux R, Stem Y, Mulvey K, Coté L. Reappraisal of temporary levodopa withdrawal ("drug holidays") in Parkinson's disease. N Engl J Med 1985:313:724-728.
47. Weiner WJ, Koller WC, Perlik S, Nausieda PA, Klawans HL. Drug holiday and management of Parkinson's disease. Neurology 1980:30:1257-1261.
48. Klawans HL, Goetz CG, Tanner CM, Nausieda PA, Weiner WJ. Levodopa-free periods ("drag holiday") in the management of parkinsonism. Adv Neural 1983:37:33-43.
49. Sweet RD, Lee JE, Spiegel H, McDowell F. Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 1972:22:520-525.
50. Hale MS, Bellizzi J. Low dose perphenazine and levodopa/ carbidopa therapy in a patient with parkinsonism and a psychotic illness. J Nerv Ment Dis 1980:168:312-314.
51. Crow TJ, Johnstone EC, McClelland HA. The coincidence of schizophrenia and parkinsonism: somèneurochemical implications. Psychol Med 1976:6:227-233.
52. Hurwitz TA, Calne DB, Waterman K.-Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neural Sci 1988:15:32-34.
53. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for treatment of drug-induced psychosis in Parkinson's disease. J Neuropsycliialry Clin Neurosci 1995;7: 304-307.
54. Friedman JH, Max J, Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient; long term treatment with clozapine and L-dopa. Clin Neurophannacol 1987:10:470-475.
55. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992:53:373-376.
56. Scholz E, Dichgens J. Treatment of drug induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neural Sci 1985;235:60-64.
57. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989:39:1219-1221.
58. Lew MF, Waters C. Clozapine treatment of parkinsonism with psychosis. J Am Gerialr Soc 1993:41:669-671.
59. Friedman JH, Gordon N. ECT In Parkinson's disease. Convuls Ther 1992:8:204-210.
60. Douyon R, Serby M, Lutchko B, et al. ECT in Parkinson's disease revisited: a "naturalistic" study. Am J Psychiatry 1989;146: 1451-1455.
61. Brown GI. Parkinsonism depression and ECT. Am J Psychiatry 1975;132:1084.
62. Fochtmann L. A mechanism for the efficacy of ECT in Parkinson's disease. Com-uls Tlier 1988;4:321-327.
63. Abrams R. ECT for Parkinson's disease. Am J Psychiatry 1989; 146:1391-1393.
64. Stem MB. Electroconvulsive therapy in untreated Parkinson's disease. Mov Disord 1991;6:265.
65. Balldin J, Granerus AK, Modigh K, et al. Electroconvulsive therapy in Parkinson's syndrome with "on/off" phenomenon. J Neural Transm 1980;47:11-21.
66. Granerus AK, Ekman R, Fall PA, Wolinder J. ECT in Parkinson's disease-predictors to improvement. Presented at International Symposium on Parkinson's Disease, Rome, Italy, April 1994.
67. Greene P. Clozapine therapeutic plunge in patient with Parkinson's disease. Lancet 1995;345:1172-1173.
68. Wolters EC, Hurwitz RE, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminergic psychosis. Neurology 1990;40:832-834.
69. Ostergaard K, Dupont E. Clozapine treatment of drug induced psychotic symptoms in later stages of Parkinson's disease. Acta Neural Scand 1988;78:349-350.
70. Roberts HE, Dean RC, Stoudemire A. A clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989;1:190-192.
71. Bear J, Lawson W, Bums S, Tarke U. Clozapine in idiopathic Parkinson's. Biol Psychiatry 1989;25:163A.
72. Pfeiffer RF, Rang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990:5:239-242.
73. Bernardi F, Del Zompa M. Clozapine in the management of psychosis in idiopathic Parkinson's Uisease. Neurology 1990;40: 1151.
74. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991:41:1699-1700.
75. Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991:14:273-278.
76. Linazasaro G, Suarez JA. Clozapine in Parkinson's disease: three years experience [Abstract]. Mov Disord 1992;7(suppl 1):100.
77. Gershanik O, Garcia S, Papa S, Scipioni O. Analysis of the mechanism of action of clozapine in Parkinson's disease [Abstract]. Mov Disord 1992;7(suppl 1):101.
78. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a two year open trial in Parkinson's disease patients with psychosis. Neurology 1994:44:544-546.
79. Friedman JH, Lannon MC, Caley C. Clozapine for movement disorder patients: a retrospective analysis of 38 patients [Abstract]. Ann Neural 1992;32:277.
80. Rosenthal SH, Fenton ML, Hamett DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hasp Psychiatry 1992; 14:285-286.
81. Parsa MA, Ramirez LF, Loula EC, Meltzer HY. Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 1991;11:330-331.
82. Pinter MM, Heischer RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neurol Transm 1991;5:135-146.
83. Rabey JM, Trevas TA, Orlov E, Katy T, Korczyn AD. Low dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995:45:432-434.
84. Trosch RM. Other effects of clozapine on Parkinson's disease [Abstract]. Mov Disord 9:1994:485.
85. Brewer MA, Kurth MC, Imke SC, Lieberman AN. Safety and effectiveness of clozapine for parkinsonian patients with psychosis [Abstract]. Neurology 1995;45(suppl 4):A252.
86. Koller WC, Pahwa R, Lyons K, Smith D. Low dose clozapine in the treatment of levodopa induced psychosis [Abstract]. Mov Disord 1994;9(suppl 1):54.
87. Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995;7: 471-475.
88. Trosch RM, Clozapine collaborative group. Clozapine use in Parkinson's disease [Abstract]. Neurology 1996;46:A375-A376.
89. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-131.
90. Findley LF. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. 2nd ed. Baltimore: Williams & Wilkins, 1988:293-314.
91. Boshes B. Further insights into parkinsonian tremor. In: Birkmeyer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Roche, 1976:xx-xx.
92. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neural Scand 1986:73:295-297.
93. Friedman JH, Lannon MC. Clozapine treatment of tremor in Parkinson's disease. Mov Disord 1990;5:225-229.
94. Fischer PA, Bass H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm 1990;2:233-238.
95. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neural Scand 1994:89:262-265.
96. Friedman JH, Koller W, Goldstein S, Lannon M, Wilterdink J. BCLOZ: a double-blind, crossover trial comparing clozapine with benztropine for treatment in Parkinson's disease [Abstract]. Neurology 1996;46(suppl):A476.
97. Koller WC. Pharmacologie treatment of parkinsonian tremor. Arch Neural 1987;44:921-923.
98. Arevalo GJG, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 1993;8:349-354.
99. Bennett JP Jr., Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993:43:1551-1555.
100. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease III. Moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-114.
101. Durif F, Vidailhet M, Bonnet AM, Agid Y. Levodopa-induced dyskinesias are improved by low-dose clozapine [Abstract]. Neurology 1996;46(suppl):A476.
102. Trosch RM, Friedman JH, LeWitt PA. Clozapine treatment of dystonia in Parkinson's disease [Abstract]. Mov Disord 1994;9 (suppl 1):102.
103. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8:171-174.
104. Juncos JL. Clozapine treatment of parkinsonian pain syndromes [Abstract]. Mov Disord 1996; 11:603-604.
105. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993;5: 206-208.
106. Rich SA, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56: 556-559.
107. Parsa MA, Simon M, Dubrow C, Ramirez LF, Meltzer HY. Psychiatric manifestations of olivo-ponto-cerebellar atrophy treated with clozapine. Int J Psychiatr Med 1993;23:149-156.
108. Simoes F, Garrett C, Ramos H, et al. Clozapine in the treatment of patients with tremor (parkinsonian, essential and neurolepticalinduced) [Abstract], Mov Disord 1992;7(suppl):47.
109. Ceravolo R, Salvetti S, Dell'Agnello G, D'Avino C, Bonuccelli U. Pharmacological tools in the study of essential tremor. Mov Dlsord 1996;ll(suppl 1):255.
110. Caine ED, Jolinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorder. Am J Psychiatry 1979:136:317-320.
111. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's disease. Neurology 1994; 44:821-823.
112. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 1991;41: 156.
113. Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease [Letter]. Neurology 1995;45:1023.
114. 113a. van Vugt JPP, Siesling S, Vergeer M, van der Velde EA, Roos RAC. Clozapine versus placebo in Huntington's disease [Abstract]. Mov Dlsord 1996;11(suppl 1):54.
115. Bashir K, Manyam BV. Clozapine for the control of hemiballismus. Clin Neurophannacol 1994;17:477-480.
116. Thiel A, Dressler D, Kistel C, Ruther E. Clozapine treatment of spasmodic torticollis. Neurology 1994;44:957-958.
117. Khot V, Egan MF, Hyde TM, Wyatt RJ. Neuroleptics and classical tardive dyskinesia. In: Lang AE, Weiner WJ, eds. Drug induced movement disorders. Mt. Kisco, NY: Futura, 1992:121-166.
118. Burke RE. Neuroleptic-induced tardive dykinesia variants. In: Lang AE, Weiner WJ, eds. Drug induced movement disorders. Mt. Kisco, NY: Futura, 1992:167-198.
119. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychophannacology 1989;99:S47-S53.
120. Jenner P, Marsden CD. Neuroleptics and tardive dyskinesia. In: Coyle JT, Enna SJ, eds. Neuroleptics: neurochemical, behavioral, and clinical perspectives. New York: Raven Press, 1983:223-253.
121. See RE, Ellison G. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Euro J Pharmacol 1990; 181:175-186.
122. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9 suppl B):102-106.
123. Davé M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994:35:886-887.
124. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54:327-330.
125. Gerlach J. Current views on tardive dyskinesia. Pharmacopsychiatry 1991;24:47-48.
126. Wilson WH. Clinical review of clozapine treatment in a state psychiatric hospital. Hasp Community Psychiatry 1992:43:700-703.
127. Meltzer HY, Luchins DL. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychophannacol 1984;4:286-287.
128. Jeste DV, Wyatt RJ. Clozapine and tardive dyskinesia. Arch Gen Psychiatry 1983;40:347-348.
129. Gerlach J, Koppelhus P, Heiwez E. Clozapine and haloperidol in a single-blind crossover trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974;50: 410-424.
130. Simpson G, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesias. Psychophannacology 1978;56:75-80.
131. Cole JO, Gardos G, Tarsy D, et al. Drug trials in persistent dyskinesia. In: Tardive dyskinesia, research and treatment. New York: SP Medical and Scientific Books, 1980:419-427.
132. Gerbino L, Shopsin B, Collra M. Clozapine in the treatment of tardive dyskinesias: an interim report. In: Fann WE, Smith RC, Davis JM, eds. Tardive dyskinesias, research and treatment. New York: SP Medical and Scientific Books, 1980:475-489.
133. Small JG, Milstein V, Markenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis. J Clin Psychiatry 1987;48:263-267.
134. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510.
135. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Ment Health Sen 1993;31:1418.
136. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(9 suppl B):107-109.
137. Carroll BJ, Curtiss CG, Kokmen E. Paradoxical response to dopaminergic agonists in tardive dyskinesia. Am J Psychiatry 1977; 134:785-790.
138. Van Putten T, Wirshing WS, Marder SR. Tardive Meige syndrome responsive to clozapine. J clin Psychopharmacol 1990; 10:381-382.
139. Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: case report and hypotheses. Mov Disord 1994;9:441-446.
140. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993;181:137-138.
141. Blake LM, Marks RC, Nierman P, Luchins DJ. Clozapine and clonazepam in tardive dystonia. J Clin Psychophannacol 1991; 11:268-269.
142. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases. Mov Disord 1994;9:321-324.
143. Bonuccelli U, Abbruzzese G, Ceravolo R, et al. Successful treatment with clozapine in 4 patients with tardive dystonia [Abstract]. Mov Disord 1996; 11(suppl 1):220.
144. Valevski A, Radvan M, Hermesh H, Sigler M, Kalef E, Weizman A. Successful treatment of severe generalized dystonia with clozapine [Abstract]. Movord 1996;11(suppl 1):230.
145. Borg M, Chatel M. Treatment of axial tardive dystonia with clozapine [Abstract]. Mov Disord 1996;11(suppl 1):212.
146. Jaffe E, Tremeau F, Sharif Z, Reider R. Clozapine in tardive Tourette's syndrome. Blol Psychiatry 1995;38:196-197.
147. Wolters ECh, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminoraimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
148. Eyatt ML, Jewart D, Juncos JL. "Seroquel" (ICI 204,636) treatment of psychosis in parkinsonism [Abstract]. Mov Disord 1996; 11:595.